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Abstract: One of the research challenges in oncology is to develop new biochemical methods for noninvasive 
tumor therapy evaluation to determine whether the chemotherapeutics is effective. Vascular endothelial growth 
factor (VEGF) was labeled with radioiodine and evaluated in vitro as well as in vivo, using A2058, a melanoma 
cell line overexpressing VEGFR-1 and -2. Saturation binding analysis with [125I]-VEGF resulted in a Kd of  
0.1 nM. Internalization assays indicate the preserved ligand induced internalization and metabolization of the 
tracer. Biodistribution studies with [123I]-VEGF in wild type and A2058 tumor-bearing athymic mice showed 
low background activity and a tumor to reference tissue ratio of maximum 6.12. These results suggest that [123I]-
VEGF is a potentially suitable tracer for tumor therapy evaluation. 
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1. Introduction 
Angiogenesis plays an essential role in embryogenesis, normal tissue growth, wound healing and the female 
reproductive cycle. It also plays a major role in various diseases. Special interest is focused on tumor growth, 
since tumors cannot grow more than a few millimeters in size without developing a new blood supply. 
Among others, vascular endothelial growth factor (VEGF-A) is one of the key molecules for angiogenesis and 
for the survival of the endothelium. It is a specific endothelial cell mitogen and a strong vascular permeability 
factor. VEGF-A is a heparin-binding glycoprotein, secreted as a homodimer of 45 kDa by many different cell 
types. Several variants of VEGF-A have been described, but VEGF165 is the most predominant protein. VEGF-A 
transcription is highly activated by hypoxia and by oncogenes like H-ras and several transmembrane tyrosine 
kinases, such as epidermal growth factor receptor and erbB2. Together, these pathways account for a significant 
up-regulation of VEGF-A in tumors compared to normal tissues and are of prognostic importance [1,12]. VEGF 
signaling is mediated mainly by two receptors: VEGFR-1 (Kd= 10-20 pM for VEGF165) and VEGFR-2  
(Kd=75-125 pM for VEGF165). The affinity for the VEGFR-1 is higher, but the cellular response is mainly 
dominated by VEGFR-2 [2]. 
One of the research challenges in oncology is to develop new biochemical methods for tumor therapy evaluation 
to determine whether the chemotherapeutics is effective [3,4]. This article presents the evaluation of the [123/125I]-
VEGF165 for future use as a radiodiagnostic to evaluate the effect of farnesyl transferase inhibitors in tumor-
inoculated athymic mouse models. Although [123I]-VEGF165 and [123I]-VEGF121 have been used before in vitro as 
well as in patients by Li et al. [5,6], biodistribution studies in animals, which are of prior importance, are not 
reported. Li also showed that the labeled VEGF165 isoform showed affinity to more cell lines than the VEGF121 
and is therefore preferred in this study. 
The synthesis, in vitro evaluation of and biodistribution of [123I]-VEGF165 in wild-type NMRI mice as well as in 
tumor-bearing athymic mice are reported and discussed. If the parameters of the radiopharmacon, mainly 
kinetics and tumor uptake ratios, are sufficient, in vivo therapy evaluation is considered for chemotherapeutics 
that interfere with the VEGFR pathway, such as tyrosine kinase inhibitors or farnesyl transferase inhibitors [1]. 
2. Materials and methods 
2.1. Synthesis of [123I]-VEGF and [125I]-VEGF 
Synthesis of both radioligands was performed in similar conditions, using the Iodogen technique. Iodogen (1,3,4, 
6-tetrachloro-3α,6α-diphenylglycouracil, Pierce, Aalst, Belgium) was coated to polypropylene vials using 70 µg 
of Iodogen per 200 µl of chloroform per vial (Aldrich, Bornem, Belgium). After evaporation of the solvent under 
N2-atmosphere at room temperature, the vials were stored at 4°C. Two micrograms of VEGF (Peprotech, 
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London, UK) and the required amount of carrier- free Na123I or Na125I (Bristol-Meyers Squibb, Brussels, 
Belgium) was added to a Iodogen-coated vial. Total reaction volume was adjusted to 140 µl, using a 0.1 M 
potassium phosphate buffer at pH 8.5. After 10 min at room temperature the mixture was removed from the 
Iodogen vial to stop the reaction. Bovine serum albumin (BSA) solution was added (Sigma, Bornem, Belgium; 
250 mg BSA per 100 ml 0.1 M phosphate-buffered saline [PBS] at pH 7.2, referred to as PBS/BSA). VEGF 
tracer and remaining radio-iodide were separated using a standard prepacked PD-10 SEC column (Size 
Exclusion Chromatography, Amersham Pharmacia Biotech, Uppsala, Sweden) using PBS/BSA as eluent [7]. 
The adsorption of the tracer to the preparative SEC column was checked using an already purified [123I]-
VEGF165 solution in PBS/BSA. From this adsorption value and the initial mass of protein used, the molar 
fraction eluted from the column was calculated. Specific activity was calculated as the amount of radioactivity 
per microgram of VEGF165 recovered at end of purification. Quality control was performed using SEC-HPLC 
and the radiochemical purity was calculated. Stability of the tracer was assessed in both PBS and DMEM growth 
medium (Bio-Whittaker, Verviers, Belgium) after various times of incubation, using PD-10 separation. 
2.2. Cell cultures and binding assay 
A2058 (human melanoma) cells were cultured in DMEM (Gibco, Paisley, UK), enriched with 10% of fetal 
bovine serum (FBS, Gibco), supplemented with 1% penicillin-streptomycin mixture (Bio-Whittaker) and  
1% L-glutamine (Bio-Whittaker). Split ratios were 1:20 weekly. Both cell lines grew in an anchorage-dependent 
manner in tissue culture flasks and Falcon 12-well tissue culture plates (Novolab, Belgium). 
Saturation binding analysis was performed on A2058 cells in 12-well cell culture plates, using three wells for 
each data point. After stripping of all receptor-bound proteins, using 0.1 M glycine-HCl buffer (pH 3), basic 
medium without FBS and increasing amounts of [125I]-VEGF165 radiotracer were added to the cells. The total 
incubation volume was adjusted to 1 ml. The cells were incubated for a period of 2 h at 4°C to avoid 
internalization. After 2 h, the supernatant was removed and the cells were washed with 1 ml of cold PBS (4°C). 
The supernatant and washing buffer were pooled and counted for radioactivity ("free ligand") with an automated 
NaI(Tl) gamma counter (CobraII Series, Canberra Packard, Meriden, CT). Two hundred microliters of trypsin-
EDTA was added to the cells and incubated at 37°C for 10 min. After addition of 1800 µl of PBS, the suspension 
was removed and counted for radioactivity ("bound"). This experiment was repeated three times. Saturation plots 
were calculated using the Prism Graph Pad software (Graphpad Software), resulting in best fits for Kd, Bmax and 
nonspecific binding coefficient [8]. Results were normalized for cell count, which was obtained from parallel 
cell culture plates, using the trypan blue method. Also, a displacement experiment with unlabeled VEGF was 
carried out on A2058 cells, as described by Li et al. to examine the specificity of the binding of the tracer. 
In order to investigate tracer internalization, A2058 cells, grown in 12-well tissue culture plates, using three 
wells per data point, were incubated at 37°C for various times (ranging from 20 min to 3 h) in the presence of 0.7 
nM [125I]-VEGF165. After incubation, the supernatant was removed; cells were washed with basic medium and 
treated with 0.1 M glycine-HCl buffer (pH 2.5) for 6 min at 4°C to remove surface-bound ligand. Cells were 
detached using 200 µl NaOH solution (1 M, incubation for 30 min at 37°C), re-suspended with 800 µl of water, 
removed and counted for radioactivity [4,9]. This experiment was repeated three times. 
2.3. Biodistribution of [123I]-VEGF165
Both male white NMRI mice (20-25 g) and male Swiss nu/nu mice (nude, 20-25 g) were purchased from Bio-
services (Schaijk, The Netherlands). All animals were treated according to the regulations of the Belgian law and 
animal experiments were approved by the local ethical committee. All manipulations with Swiss nu/nu mice 
were carried out in sterile conditions. 
Biodistribution on tumor-bearing mice was carried out using A2058 tumors. Cells were harvested by 
trypsinization or using a cell scraper in growth medium. After centrifugation for 5 min at 100 xg, cells were 
resuspended in serum-free growth medium. Cells were counted using the trypan blue method. Male Swiss nu/nu 
athymic mice were injected subcutaneously in the right flank with a suspension of approximately 5xl06 A2058 
cells in a total volume of 200 µl serum-free growth medium. Tumor growth curves were obtained using daily 
sliding caliper measurement. Tumor volume was calculated as V=0.4 a2b, a and b being the short-axis and the 
long-axis of the tumor, respectively. Tumor-bearing mice were used in the biodistribution studies when tumor 
volume was approximately 1 ml. 
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NMRI and tumor-bearing nude mice were both injected intravenously through the lateral tail vein with a 100 µl 
solution of 2 µCi of [123I]-VEGF165 (4 µCi per 100 µl for all intervals longer than 2 h). At various time points 
(20 s to 48 h for NMRI mice and 1 to 6 h for tumor-bearing nude mice) postinjection (p.i.), the animals were 
sacrificed by decapitation and blood was recovered (n =3 per time point). All organs (lung, liver, stomach, 
spleen, bladder, large and small intestines, mesenterium, brain, skin, muscle, tail and heart) were removed, 
briefly washed in physiological saline to remove blood, dried, weighed and counted for radioactivity using an 
automated NaI(Tl) gamma counter (CobraII Series). In case of tumor-bearing mice, also the left thigh muscle 
(reference tissue) and the tumor were dissected and treated as mentioned above. Blood was weighed and counted 
like the organs. The injected activity was calculated by weighing the syringes before and after injection and by 
the use of a dilution series of the injected tracer solution, which is also weighed and counted for radioactivity 
using the same CobraII gamma counter. The concentration of radioactivity in the organs was expressed as 
percentage of the injected dose per gram of tissue (%ID/g). Excretion was recovered and counted for 
radioactivity and expressed as %ID [7,9]. Results for tumor uptake were expressed as a ratio %ID/g tumor vs. 
left thigh muscle as a reference organ. 
2.4. In vivo imaging 
Dynamic gamma camera imaging was performed in NMRI mice using a Toshiba GCA-9300 A/hg SPECT 
camera in the planar mode equipped with a high-resolution parallel-hole collimator. All images were acquired 
into 128x128 matrices (FOV: 23.5x12.46 cm) and with a photopeak window set at 15% around 159 keV. At the 
same time a syringe with a known amount of radioactivity was scanned to allow the semiquantification of the 
results of the ROI analysis. The animals were anesthetized intraperitoneally with 75 µl (1.5 mg) of a 
pentobarbital solution (Nembutal, 20 mg/ml, Ceva Santé Animale, Belgium) before starting the imaging 
experiments. After sedation, 3.7 MBq of [123I]-VEGF165 was injected via the lateral tail vein. Eighty images of 
1 min each were taken. ROIs were drawn using a MRI maximum intensity projection [10]. 
Fig. 1: Representative chromatogram of the preparative purification of [123I]-VEGF165 with a PD-10 column. 
The first peak at fractions 7-10 reflects the elution of the labeled compound. The second peak at fractions 18-20 
reflects the elution of the remaining free iodine isotope. 
 
Table 1: Stability of [125I]-VEGF at 4 and 24 h after start of incubation at 20°C or 37°C in PBS or DMEM 
PBS DMEM Temperature 
(°C) 4 h (%) 24 h (%) 4 h (%) 24 h (%)
20 97 77 96 70 
37 87 - - - 
The stability is expressed as the percentage of intact native labeled peptide (n =3, standard deviations were < 1%). 
In order to exclude that increased vascularization is the cause of the tumor to muscle ratio of 6.12 (±2.11), a 
99mTc-HSA (human serum albumin) planar scintigraphy scan was performed to look at blood flow. Animals 
(n=5) were sedated as described above and injected with 3.7 MBq of 99mTc-HSA. One static image was taken 
from 5 to 10 min p.i. Also, a displacement study was performed using 80 µg of VEGF165, co-injected with the 
tracer. Six animals bearing an A2058 tumor were scanned with [123I]-VEGF165 by planar scintigraphy at 2 h p.i. 
as described in vivo imaging to obtain a "baseline" uptake. Before taking a second scan, three of the animals 
were treated with vehicle (PBS) and three were injected intravenously with 80 µg of VEGF165. In order to give 
more evidence for the specific targeting of the VEGFR, one more experiment was performed. Another cell line, 
CAPAN-II, which is VEGFR-negative, was inoculated in 5 athymic mice. The uptake of the tracer was measured 
by dissection as described, 2 h p.i. 
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3. Results and discussion 
3.1. Synthesis of [123I]-VEGFI65 and [125I]-VEGFI65
The overall radiochemical yield using freshly prepared Iodogen vials is 37% for [123I]-VEGF165 and for [125I]-
VEGF165. A representative chromatogram of the purification step for the 123I compound is shown in Fig. 1. An 
elution of purified [123I]-VEGF165 with PBS/BSA on PD-10 gives rise to a total eluted fraction of 80%. 
Nonspecific adsorption on the PD-10 column cannot be decreased using increasing amounts of BSA. 
Radiochemical purity of the 123I tracer recovered at end of synthesis was >95%. Stability of the 123I tracer was 
>96% for a 4-h incubation period in PBS or DMEM cell growth medium (Table 1). Specific activity for [125I]-
VEGF165 was 14.2 MBq/mmol. Specific activities of the [123I]-VEGF165 tracer were 1.66 108 MBq/mmol (3.7 
MBq/1 µg injected) for planar scintigraphy, and 3330 or 1665 GBq/mmol for biodistribution studies (74 or  
148 kBq/1 µg injected, respectively). 
3.2. In vitro assays 
Saturation binding plot of [125I]-VEGF165 on A2058 cells is shown in Fig. 2. Nonlinear regression reveals 
Kd=0.11±0.06 nM and Bmax=9254 ±702 receptors per cell. This is in correlation to the results of Li et al [5], 
which show a Kd ranging from 0.060 to 0.236 nM. Nonspecific binding was low (NSB coefficient=4.3 X 10-4). 
The IC50 value for displacement of [123I]-VEGF165 with native VEGF165 was 0.15±0.02 nM. This corresponds to 
the displacement studies by Li et al., which showed IC50 values on various cell lines ranging from 0.009 to  
0.245 nM. 
Fig. 2: Saturation binding plot of [125I]-VEGF165 on A2058 cells. Kd=0.1±0.05 nM and Bmax=9453±302 
receptors per cell (n =3). Nonspecific binding, specific binding and total binding are represented as curves in 
the graph. 
 
The internalization assay showed uptake of activity in A2058 cells (Fig. 3). The internalized fraction was 
maximal at 5 h. Afterwards, the curve shows a decrease. The [125I]-VEGF165 binds to its receptor and is 
internalized by ligand-induced endocytosis of the VEGF-VEGFR complex. Afterwards, the vesicle containing 
the peptide is merged with a lysosome and the tracer is metabolized, resulting in rapid excretion of free 123I- and 
[123I]-iodotyrosine. Moreover, these results indicate that the ligand-receptor interaction has remained intact after 
iodination of the VEGF165. The possible drawback of the internalization is the metabolization of the tracer and 
the increased background caused by the secreted products. 
3.3. Biodistribution of [123I]-VEGF165 and in vivo imaging 
Biodistribution of [123I]-VEGF165 in NMRI mice showed radioactivity uptake in kidneys (30.1 ± 11.2% ID at 1.5 
min), liver (14.6±4.9% ID at 1.5 min) and stomach (13.2±3.5% ID at 3 h). A small uptake was seen in the small 
and large bowel (Figs. 4A and 5). Low background activity was observed in lungs, heart, body and head 
(containing the thyroid, which was not dissected separately). When compared to other iodinated peptides, such 
as [123I]-annexin V [7] or [123I]-hEGF [11], the rather low dehalogenation profile, as observed in the stomach, is 
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remarkable. Although stomach uptake is still significantly high, it is up to 4 times as low as compared to the 
other abovementioned radioiodinated peptides. The latter is also confirmed by ROI analysis on both stomach and 
thyroid on the planar gamma images. Bladder content activity, due to free radioiodine and [123I]-iodotyrosine 
excretion through the kidneys to the bladder, is found to be high. Background levels in the lungs and intestines 
are strikingly low, as shown by both biodistribution and planar gamma camera images. These results would 
make it possible to image tumors, overexpressing the VEGFR-1 or -2 receptors, located in these areas. 
Biodistribution in A2058 tumor-bearing athymic mice (Fig. 4B) resulted in a ratio of the %ID/g of the tumor vs. 
thigh of 0.40±0.14, 6.12±2.11, 1.16±0.30 and 0.48±0.12 at 1, 2, 4 and 6 h p.i., respectively. Other organs did not 
differ significantly from the results obtained from NMRI mice. The 99mTc-HSA study shows that the uptake of 
[123I]-VEGF165 in the tumor is not due to increased tumor perfusion: it showed a tumor to muscle ratio of 1.17 
(±0.09). 
Baseline uptake at 2 h p.i. in A2058-bearing mice resulted in a tumor vs. thigh ratio of 6.01 ±1.95. Vehicle 
treatment showed no significant difference (ratio= 6.26±1.50; P>>.05). However, co-injection of 80 µg of 
VEGF165 resulted in a significant decrease of the A2058 tumor uptake (ratio = 1.30±0.34; P<.05). These results, 
added with the in vitro displacement study, suggest the specific uptake of the tracer in the tumor. Ratio tumor vs. 
thigh   of the   CAPAN-II-bearing mice was 1.11±0.23. 
Because of the absence of labeled catabolites of the tracer, only the native [123I]-VEGF165 and free radioiodine 
are present in plasma. Of these, only the labeled VEGF165 can bind to the VEGFR, confirmed by the in vitro 
displacement experiment. 




Given the preserved receptor-ligand interactions and the high receptor affinity, its low in vivo background 
activity due to relatively low dehalogenation and good tumor uptake, we conclude that [123I]-VEGF165 is a potent 
tool to perform VEGF receptor scintigraphy in vivo. 
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Fig. 4: Biodistribution results of [123I]-VEGF165 in wild-type NMRI mice (A) and A2058-inoculated nu/nu mice 
(B). 
 
Fig. 5: Planar gamma camera image of an NMRI mouse (wild type) injected with 3.7 MBq of [123I]-VEGF165 at 
20 min (left) and 1 h (right) post intravenous injection. 
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